Radiopharm Theranostics (ASX:RAD) raise $5 million via the execution of a subscription agreement for a private placement of 133 million ordinary shares to Lantheus Holdings, according to a Friday Australian bourse filing.
After the placement, Lantheus' shareholding in the firm rose to 12.16%.
The placement was completed at an issue price of AU$0.06 apiece, and under Radiopharm's existing
placement capacity.
The radiopharmaceuticals firm will use the funds for the development of its clinical pipeline.
The placement replaces the six-month options that it issued in August 2024.
The firm's shares surged 58% in recent trade on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.